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To see if variations in timing of rapamycin (Rapa), administered to middle aged mice 
starting at 20 months, would lead to different survival outcomes, we compared three 
dosing	regimens.	Initiation	of	Rapa	at	42	ppm	increased	survival	significantly	in	both	
male and female mice. Exposure to Rapa for a 3-month period led to significant 
longevity benefit in males only. Protocols in which each month of Rapa treatment 
was followed by a month without Rapa exposure were also effective in both sexes, 
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1  |  INTRODUC TION
The	NIA	 Interventions	Testing	Program	(ITP)	showed	 in	2009	that	
male	or	female	mice	given	the	mTORC1	inhibitor	rapamycin	(Rapa)	
from age 20 months had a significant increase in median lifespan 
(Harrison et al., 2009) and also increased the proportion of mice alive 
at the 90th percentile survival age. Subsequent reports documented 
a similar degree of lifespan extension in mice given this drug starting 
from 9 months of age (Miller et al., 2011) and that the degree of 
extension was dependent on Rapa dose over the range of 4.7–42 
parts per million (ppm) in food (Miller et al., 2014). The combination 
of Rapa with metformin led to as much as a 26% increase in female 
median lifespan and 23% increase in median male lifespan (Strong 
et al., 2016), although these survival results were not significantly 
higher than those noted in earlier experiments using the same dose 
(14.7 ppm) of Rapa by itself. Mice treated with Rapa (14.7 ppm) from 
9 months and then euthanized at 22 months showed lower incidence 
of pathological changes in heart, tendon, adrenal, endometrium, and 
liver (Wilkinson et al., 2012), among other organs, suggesting that 
many aspects of aging were delayed or decelerated by Rapa, and 
that this retardation of age-related changes was responsible for 
postponement of lethal illnesses and lifespan extension. Studies 
with higher doses of rapamycin, delivered either orally or intraper-
itoneally, also had beneficial effects on lifespan extension and on 
cancer incidence (Bitto et al., 2016).
Because it is possible that Rapa could create a mixture of bene-
ficial and harmful effects, we considered the possibility that varia-
tions of dose timing might lead to further increases in lifespan when 
compared to continuous Rapa administration. We report here lon-
gevity results using three dosing schemes: “Rapa 20 mon” in which 
Rapa is given at 42 ppm from 20 months until death; “Rapa cycles” 
in which Rapa is given for 1-month interval interspersed with drug-
free months from 20 months until death; and “Rapa 20–23,” in which 
Rapa is started at 20 months but then terminated at 23 months.
The	 ITP	 reports	 the	 outcome	 of	 each	 longevity	 experi-
ment even when the agent tested did not lead to a convinc-
ing	 longevity	 benefit.	 In	 2015,	 the	 cohort	 used	 for	 the	 Rapa	
dosing	 study	 (C2015),	 the	 ITP	 also	 tested	 four	 other	 agents:	
17-dimethylaminoethylamino-17-demethoxygeldanamycin hy-
drochloride (17-DMAG), which inhibits HSP90 (Jez et al., 2003); 
Minocycline (Min), a member of a class of that includes tetracycline 
and doxycycline (Klein & Cunha, 1995); β-GPA (β-guanadinopropi-
onic acid) (β-GPA), which lowers both blood glucose and blood in-
sulin	levels,	similar	to	the	effects	of	dietary	restriction	(Ohira	et	al.,	
1994); and MitoQ, a small molecule antioxidant that accumulates in 
mitochondria in cultured cells and in vivo (Kelso et al., 2001; Smith 
et al., 2003; Smith & Murphy, 2010). None of these four agents led 
to a significant increase in lifespan.
2  |  RESULTS
Genetically heterogeneous male and female mice, from the four-way 
UM-HET3 cross, were given food containing Rapa at 42 ppm from 
20	months	of	age	at	each	of	the	three	test	sites.	One	group	of	cages	
(“Rapa 20”) received this dose for the rest of their lives. A second 
group (“Rapa cycles”) received Rapa for 1-month period interrupted 
by 1 month periods without drug. The third group (“Rapa 20–23”) 
received Rapa for the 3-month period starting at age 20 months, 
but	not	thereafter.	Kaplan–Meier	plots	are	shown	in	Figure	1,	and	
summary	statistics,	pooled	across	sites,	are	collected	in	Table	1.	In	
male mice, all three dosage schedules led to a similar increase in me-
dian lifespan (9%–11%), and all three produced a significant result 
by the log-rank test. The Wang–Allison (WA) test, which we use as 
an index of extreme longevity, was significant for Rapa 20 and Rapa 
cycles, but not (p	=	0.08)	for	the	Rapa	20–23	protocol.	Formal	com-
parisons, using the log-rank test, between each pair of treatment 
protocols found no significant difference among them for male mice 
(0.28	<	p	<	0.61).
In	contrast,	each	of	the	three	protocols	produced	a	distinctly	dif-
ferent level of benefit in female mice. Rapa 20 led to a 15% increase 
in median (p	<	0.0001	by	log-rank	test),	while	Rapa	cycles	led	to	an	
8%	increase	(p	<	0.0001)	and	Rapa	20–23	led	to	a	mere	4%	increase	
in median survival (p = 0.15). The first two of these protocols also 
led to a significant result with the WA test (p	<	0.0004	in	each	case),	
but Rapa 20–23 did not (p = 0.12). Pairwise comparisons among the 
on Aging, Grant/Award Number: 




though this approach was less effective than continuous exposure in female mice. 
Interpretation	of	these	results	is	made	more	complicated	by	unanticipated	variation	in	
patterns of weight gain, prior to the initiation of the Rapa treatment, presumably due 
to the use of drug-free food from two different suppliers. The experimental design 
included tests of four other drugs, minocycline, β-guanidinopropionic acid, MitoQ, 
and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), but none 
of these led to a change in survival in either sex.
K E Y W O R D S
17-DMAG, minocycline, MitoQ, rapamycin, survival, β-GPA
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three dose protocols by log-rank test showed that each one differed 
from the other two, with p-values ranging from 0.04 to 0.0001.
Although our pre-specified analytical method gives first priority 
to evaluation of the pooled data sets, we also evaluate site-specific 
results, even though each site has only one third of the mice in the 
pooled set, and therefore far lower statistical power. Survival plots 
for each combination of sex, site, and Rapa protocol are shown in 
Figure	S1,	and	site-specific	statistics	are	collected	in	Table	S1.	These	
revealed	a	striking	degree	of	site-specific	variation.	For	female	mice,	
each site showed the same pattern, that is, significant effects of the 
Rapa 20 and Rapa cycles protocol, and the absence of significant 
benefit using the Rapa 20–23 protocol, but the extent of change in 
median varied a great deal, with the UM females typically showing 
the smallest percentage increase in median lifespan. All three sites 
showed a similar degree of increase in the 90th percentile age for 
the	Rapa	20	and	Rapa	cycles	treatment	group.	In	males,	however,	re-
sponses to Rapa 20 varied from 0% to 16% increase in median (rank 




ity of unanticipated artifacts with effects on lifespan because survival 
curves at several sites appear to show differences between Control 
and treatment cohorts prior to the initiation of Rapa administration 
at age 20 months (604 days). At UM, for example, each of the three 
groups of male mice, randomly assigned at weaning to one of the Rapa 
treatment protocols, had fewer deaths than the Control mice prior to 
the onset of Rapa treatment at 604 days. Similar phenomena are vis-
ible	in	Figure	S1	for	TJL	females	and	UT	males.	We	suspect	this	may	
reflect unanticipated differences between the chow provided to these 
mice prior to 604 days; although both the Control cages and those 
destined for Rapa treatment received food with the same formula 
(Purina	5LG6),	mice	in	the	Control	group	received	chow	prepared,	by	
TestDiets,	 using	 the	 equipment	 employed	 for	 production	 of	 all	 ITP	
drug/food	mixtures,	while	mice	in	the	Rapa	group	received	5LG6	from	
a different supplier prior to 604 days of age.
F I G U R E  1 Kaplan–Meier	survival	plots	for	female	and	male	mice	exposed	to	different	Rapa	treatment	schedules.	Green	circles:	Rapa	
given from 22 months until death. Red squares: Rapa given from 20–21, 22–23, 24–25, etc., until death. Cyan diamonds: Rapa given for 
3 months only, starting at 20 months. Data are pooled from all three test sites
TA B L E  1 Survival	statistics	for	mice	treated	with	Rapamycin	using	various	dosage	schedules,	pooled	across	sites














Controls Pool M 300 772 1049
Rapa 20 mon Pool M 156 856 11 0.0007 1148 9 0.04
Rapa cycles Pool M 159 841 9 0.002 1144 9 0.001
Rapa 20–23 Pool M 153 854 11 0.024 1100 5 0.08
Controls Pool F 280 905 1095
Rapa 20 mon Pool F 136 1040 15 <0.0001 1231 12 <0.0001
Rapa cycles Pool F 136 977 8 <0.0001 1203 10 0.0004
Rapa 20–23 Pool F 136 940 4 0.15 1136 4 0.12
Note: p-Values derived from log-rank test, stratified by site, calculated for each sex separately. The Wang–Allison (WA) test is described in Section 4.
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Mice	in	the	 longevity	cohorts	were	weighed	at	6,	12,	18,	and	
24 months, and the mean levels for Control and the Rapa groups, 
averaged	 across	 sites,	 are	 shown	 in	 Figure	 2.	 Control	 females	
gained	weight	 until	 18	months,	 but	 lost	weight	 between	 18	 and	
24	 months,	 in	 this	 cohort	 as	 in	 previous	 ITP	 cohorts.	 Each	 of	
the three Rapa protocols accelerated the weight loss between 
Control	 and	 Rapa	 females	 after	 18	months.	 Females	 in	 all	 three	
Rapa groups were significantly lighter (p	<	0.001)	than	Controls	at	
24 months, but there were no significant differences in weight at 
18	months.	In	contrast,	males	in	each	of	the	Rapa-assigned	groups	
were	 lighter	 than	 Control	 males	 at	 12	 and	 at	 18	months	 of	 age	
(p	<	0.005	in	each	case),	that	is,	prior	to	their	first	exposure	to	Rapa	
at 20 months of age, consistent with the idea that unanticipated 
differences	 between	 the	 two	 sources	 of	 drug-free	 5LG6	mouse	
chow might have contributed to the divergence of survival curves 
prior to 20 months of age.
The cohort initiated in 2015 also included groups of mice given 
17-DMAG (30 ppm, from 6 months), Min (300 ppm, from 6 months), 
β-GPA (3300 ppm, from 6 months), or MitoQ (100 ppm, from 
7	months).	The	survival	curves	are	shown	in	Figure	3,	and	statistics	
for these agents are collected in Table 2. None of the drugs led to a 
significant change in lifespan as indicated by the log-rank test, and 
none improved the proportion of mice surviving to the 90th percen-
tile age as tested by the WA test. Corresponding statistics for each 





also differed from Controls (p = 0.03) at 12 months
F I G U R E  3 Kaplan–Meier	survival	plots	for	female	and	male	mice	treated	with	17-DMAG,	Min,	bGPA,	or	MitoQ
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individual site are presented in Table S2. None of these four agents 
produced a significant change in lifespan at any site.
3  |  DISCUSSION
Previous	 ITP	 papers	 have	 reported	 that	 encapsulated	 rapamycin	
(eRapa) extends lifespan (including an index of maximal lifespan) when 
given at 9 months of age at doses of 4.7, 14, and 42 ppm in food, with 
similar effects when given at 14.7 ppm (equivalent to 2 mg/kg body 
weight per day) starting at 20 months (Harrison et al., 2009; Miller 
et al., 2011, 2014). A dose in food of 42 ppm is equivalent to a dose of 
7 mg/kg body weight per day for a 30 g mouse eating 5 g of chow per 
day.	Other	groups	(Anisimov	et	al.,	2011;	Fok	et	al.,	2013)	have	also	
documented	 lifespan	 extension	 in	C57/BL6	 and	129/Sv	mice,	 over	
doses	ranging	from	0.7	mg/kg	body	weight	to	8	mg/kg	body	weight.	
However, negative side effects have been noted in mice treated with 
rapamycin, including cataracts, testicular degeneration (Wilkinson 
et	al.,	2012),	 insulin	 resistance	 (Fok	et	al.,	2013),	and	glucose	 intol-
erance	 (Lamming	et	al.,	2012;	Miller	et	al.,	2014).	One	approach	to	
reducing unwanted side effects of therapeutic agents is intermittent 
dosing,	 a	 common	 practice	 in	 cancer	 chemotherapy.	 Intermittent	
dosing has been reported to decrease rapamycin-induced glucose 
intolerance, reduce rapamycin-induced loss of testicular weight and 
lessen the effects of rapamycin on the immune system in 9-month-
old	male	C57BL/6	mice	(Arriola	Apelo,	Neuman,	et	al.,	2016).
In	 this	 study,	 we	 compared	 three	 different	 rapamycin	 dosing	
regimens,	 in	 parallel,	 for	 their	 effects	 on	 longevity.	 Intermittent	
treatment with rapamycin (2 mg/kg body weight per day, i.p.) ad-
ministered once every 5 days starting at 20 month of age reportedly 
extended	lifespan	in	female	C57BL/6	mice	(Arriola	Apelo,	Pumper,	
et al., 2016). Moreover, intermittent treatment of female 129/Sv 
mice with rapamycin 1.5 mg/kg body weight, three times a week 
for a period of 2 weeks, followed by 2 weeks without rapamycin, 
also increased lifespan when started at 2 months of age (Anisimov 
et al., 2011). Chen et al. (2009) reported that rapamycin adminis-
tered at 4 mg/kg body weight by intraperitoneal injection to 22- to 
24-month-old	C57BL/6	male	mice,	every	other	day	for	only	6	weeks,	
increased	 longevity	 (death	 ratio	 of	 0.8	 versus	 0.2	 death	 ratio	 at	
30	weeks	after	first	treatment).	In	the	present	study,	we	compared	
dosing schemes for microencapsulated rapamycin (eRapa) for their 
effects on survival, comparing continuous administration from 
20 months, 3-month exposure from 20 to 23 months, and treatment 
every other month beginning at 20 months of age. Continuous treat-
ment with 42-ppm eRapa starting at 20 months of age increased 
median and 90th percentile lifespan in both males and females. 
Treatment with eRapa every other month starting at 20 months of 
age increased median and 90th percentile lifespan in both males and 
females. Treatment with eRapa, starting at 20 months and stopped 
at 23 months of age, increased median lifespan in males only but did 
not lead to a significant effect on our measure of survival to the 90th 
percentile lifespan in either sex.
In	a	previous	paper,	in	which	Rapa	was	used	at	42	ppm	starting	at	
age 9 months (Miller et al., 2014), median survival was increased by 
23% in males and 26% in females. Each value is substantially higher 
than the corresponding changes seen in the current paper, (i.e., 11% 
in males and 15% in females), when the same dose of 42 ppm was 
initiated at 20 months of age. Although it is always hazardous to 
compare results from studies done many years apart, that is, using 
“historical” data rather than contemporaneous data sets, it may be 
that this Rapa dose is more effective when given starting earlier in 
adult life. This is in contrast to our evidence that the 14 ppm dose 
is equally effective regardless of age (Harrison et al., 2009; Miller 
et al., 2014).
Bitto et al. (2016) evaluated the effects of rapamycin given for 
a	3-month	period	starting	at	20–21	months	of	age,	using	C57BL/6	
mice and a dose, in chow, of 126 ppm, that is, 3-fold higher than 
the dose we used in the current study. Treated mice had a median 
survival of approximately 996 days, a 12.5% increase over the con-
trol	value	of	885	days,	pooled	across	sex.	The	paper	did	not	include	
TA B L E  2 Survival	statistics	for	mice	treated	with	17-DMAG,	Min,	bGPA	or	MitoQ,	pooled	across	sites.














Controls Pool M 300 772 1049
17-DMAG Pool M 156 844 9 0.12 1090 4 0.13
Min Pool M 156 807 5 0.99 1026 −2 0.50
bGPA Pool M 156 764 −1 0.73 1054 0 0.86
MitoQ Pool M 156 784 2 0.91 1066 2 0.86
Controls Pool F 280 905 1095
17-DMAG Pool F 136 866 −4 0.12 1074 −2 0.29
Min Pool F 136 878 −3 0.38 1094 0 0.99
bGPA Pool F 136 893 −1 0.91 1114 2 0.39
MitoQ Pool F 136 890 −2 0.67 1105 1 0.39
Note: p-Values derived from log-rank test, stratified by site, calculated for each sex separately. The Wang–Allison (WA) test is described in Section 4.
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a	formal	test	of	maximum	lifespan,	but	inspection	of	their	Figure	4	
suggests that their 3-month regime, equivalent to our Rapa 20–23 
protocol,	may	have	had	more	late-life	benefit	in	male	C57BL/6	mice	
than in females. Although differences in base diet, mouse stock, 
and vivarium conditions make a direct comparison to our own study 
impossible, it is of interest that the 12.5% increase survival in this 
3-month transient protocol is similar to that which we see in our 
Rapa 20–23 males (11%) given the 42 ppm dose, though higher than 
the 4% increase seen in our female mice.
Our	previous	study	(Miller	et	al.,	2014)	of	the	effects	of	differ-
ent doses of Rapa on lifespan showed that the increased survival in 
response to increasing concentrations of rapamycin was associated 
with higher blood levels of Rapa in females. We do not have a ready 
explanation for the sexual dimorphism we have noted in responses 
to the Rapa 20–23 dosing regime in the present study and would 
need to conduct detailed pharmacodynamic analysis of Rapa fluctu-
ations at several intervals after initiation of these dosing strategies. 
It	is	possible,	in	addition,	that	some	of	the	Rapa	effects	involve	alter-
ation	in	microbial	populations	within	the	GI	tract,	which	could	show	
variable time courses of drug-induced reconfiguration and recovery. 
Developing clinical strategies for optimal benefit in long-term Rapa 
treatment, with minimal side effects may require careful stepwise 
refinement and adjustment for sex-specific effects.
Four	other	 agents	were	 tested	 in	 the	C2015	cohort,	 but	none	
of these led to any improvement in lifespan. Each of the four had a 
plausible rationale for inclusion the study:
17-dimethylaminoethylamino-17-demethoxygeldanamycin hy-
drochloride (17-DMAG) is a third generation, orally bioavailable, 
specific HSP90 inhibitor (Jez et al., 2003). 17-DMAG is a chemi-
cally modified version of Geldanamycin, a benzoquinone antibiotic 
initially discovered in the organism Streptomyces hygroscopicus. 
17-DMAG effectively inhibits HSP90, has diverse anti-tumor ac-
tions	(Ikebe	et	al.,	2013),	and	suppresses	neurotoxicity	in	lower	or-
ganisms such as D. melanogaster	 (Zhang	et	al.,	2014).	In	addition,	it	
has	 a	 neuro-protective	 role	 in	mice	 (Silva-Fernandes	 et	 al.,	 2014),	
improves survival of animals exposed to near-lethal doses of radi-
ation	(Lu	et	al.,	2013),	and	reduces	 inflammation	(Madrigal-Matute	
et al., 2010, 2012). This spectrum of results suggested the idea that 
lifelong exposure to 17-DMAG might increase mouse longevity, but 
our data give no support for this hypothesis. The concentrations of 
17-DMAG in the food were verified in six different batches of food 
sampled over a 3 to 4-year period (see Methods S1 for methods of 
analysis). The mean ± SEM of the concentrations of 17-DMAG in the 
chow	was	30.00	±	2.18,	which	matches	the	intended	concentration.	
Thus, differences in concentration in the chow do not explain the 
current	findings.	It	is	possible	that	a	different	dose	of	17-DMAG	may	
have a positive effect on longevity.
MitoQ is a small molecule antioxidant that accumulates in mito-
chondria in cultured cells and in vivo (Kelso et al., 2001; Smith et al., 
2003;	 Smith	 et	 al.,	 2010).	 Orally	 administered	 MitoQ	 reportedly	
decreases pathology when applied to rodent models of age-related 
human diseases involving mitochondrial oxidative damage (Smith 
et al., 2011; Smith et al., 2010). These include models of cardiac 
ischemia-reperfusion	injury	(Adlam	et	al.,	2005),	Alzheimer's	disease	
(McManus	et	al.,	2011),	Parkinson's	disease	(Ghosh	et	al.,	2010),	amy-
otrophic lateral sclerosis (Miquel et al., 2014), diabetic nephropathy 
(Chacko et al., 2010), age-related arterial endothelial dysfunction 
(Gioscia-Ryan et al., 2014), and age-related macular degeneration 
(Tarallo et al., 2012). MitoQ has also been administered to humans 
in	three	studies	(Gane	et	al.,	2010;	Rossman	et	al.,	2018;	Snow	et	al.,	
2010) and was able to reverse age-associated vascular dysfunction 
in	old	but	healthy	individuals	(Rossman	et	al.,	2018).	Despite	this	va-
riety of positive effects on health indices in these various disease 
models, there were no effects on longevity in the present study. 
The concentration of MitoQ in the food was verified in four differ-
ent batches of food sampled over a 3-year period (see Methods S2 
for methods of analysis). The mean ± SEM of the concentrations of 
MitoQ	in	the	chow	was	88.00	±	19.95	ppm	which	is	consistent	with	
the intended concentrations of MitoQ in the food. Hence, a lack of 
effect of MitoQ on lifespan is not due to instability of the drug in the 
food.	 In	another	study,	however,	the	 levels	of	MitoQ	in	the	hearts	
and livers in the treated mice were below the detection limits when 
measured	 by	 LC-MS/MS	 relative	 to	 deuterated	 internal	 standards	
(Rodriguez-Cuenca et al., 2010). Hence, tissues levels in the mice in 
this study were at least ~20-fold lower than the levels that showed 
efficacy in previous mouse models of diseases. The low levels of 
MitoQ may be due to the poor bioavailability of MitoQ when mixed 
with solid food due to its strong tendency to adsorb to hydropho-
bic surfaces (Smith & Murphy, 2010). Therefore, it is not possible 
to make any robust conclusions on the impact of MitoQ on lifespan 
from this study and further studies at doses higher than the one cho-
sen in the present study may produce a different outcome.
Minocycline belongs to a class of semi-synthetic antibiotics that 
includes tetracycline, doxycycline and demeclocycline. Minocycline 
has been found to extend lifespan in worms and Drosophila 
(Oxenkrug	et	al.,	2012;	Ye	et	al.,	2014)	and	to	have	beneficial	effects	
in a wide range of rodent models of human diseases. Minocycline 
leads to improved outcomes in a mouse model of atherosclerosis 
(Shahzad et al., 2011), the transgenic APP/presenilin mouse model of 
Alzheimer's	disease	(Biscaro	et	al.,	2012),	the	MPTP	mouse	model	of	
Parkinson disease (Du et al., 2001) and after whole-body γ-irradiation 
in mice (Mehrotra et al., 2013) to name a few. Minocycline has also 
been	reported	to	have	benefits	in	human	trials.	It	was	reported	to	im-
prove refractory rheumatoid arthritis, to improve recovery in patients 
with acute stroke, to improve symptoms of fragile X syndrome, and to 
improve negative symptoms in early schizophrenia (Chaudhry et al., 
2012;	Lampl	et	al.,	2007;	Langevitz	et	al.,	1992;	Miyaoka	et	al.,	2012;	
O'Dell	et	al.,	1997;	Paribello	et	al.,	2010;	Smith	et	al.,	2011).	However,	
300 ppm minocycline did not modify lifespan in UM-HET3 mice. The 
concentration of minocycline in the food was verified in 6 different 
batches of food sampled over a four-year period (see Methods S3 for 
methods of analysis). The mean (SEM) concentration of βGPA in six 
batches	of	food	pellets	was	308	±	23.2	(SEM)	ppm,	which	was	102%	
of the expected concentration of 300 ppm on average. However, it 
is possible that concentrations higher or lower than 300 ppm may 
produce beneficial effects on longevity.
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β-GPA is a creatine analog that stimulates AMP-activated pro-
tein kinase by depleting cellular energy stores (Bergeron et al., 
2001). β-GPA treatment produces beneficial physiological effects 
that are associated with some (but not all) longevity extending 
treatments	 (Bergeron	 et	 al.,	 2001;	 Neubauer	 et	 al.,	 1998;	 Zong	
et	 al.,	 2002).	 For	 example,	β-GPA treatment of mice significantly 
lowers both blood glucose and blood insulin levels, similar to the 
effects	 of	 dietary	 restriction	 (Ohira	 et	 al.,	 1994;	 Reznick	 et	 al.,	
2007). Glucose tolerance is also improved in β-GPA treated ani-
mals, though these effects are greater in diabetic animals com-
pared	with	control	animals	(Meglasson	et	al.,	1993).	In	the	present	
study, β-GPA was added to food at a concentration of 3300 ppm 
and fed to mice beginning at 6 months of age. The concentration 
of β-GPA in the food was verified in six different batches of food 
sampled	over	a	4-year	period	3248	±	116	(SEM)	ppm	(see	Methods	
S4 for methods of analysis). Despite the beneficial physiological ef-
fects reported in various animal models, we observed no effects of 
β-GPA on survival in the present study. This is consistent with the 
results of a recent study in which β-GPA treatment had no effect on 
increasing survival in three different strains of C. elegans (Coleman-
Hulbert	et	al.,	2020).	 In	 that	study,	an	effect	on	survival	was	de-
tected in only one strain, and in that strain, β-GPA reduced lifespan.
4  |  E XPERIMENTAL PROCEDURES
4.1  |  Animals
UM-HET3 mice were produced at each of the three test sites as 
previously described in detail (Harrison et al. 2014; Miller et al., 







Mice were housed as previously described (Strong et al., 2013) in 
plastic cages with metal tops, using 1/4 inch corn-cob bedding (Bed 
O'Cobs,	produced	by	The	Andersons).	Mice	were	given	free	access	to	
water, acidified (pH 2.5–2.7) by addition of hydrochloric acid, using 
water bottles rather than an automated watering system. Mice were 
housed in ventilated cages and were transferred to fresh cages every 
14 days. Temperature was maintained within the range of 21°C to 23°C.
At the age of 42 days, each cage was assigned to a control or 
test group by use of a random number table. Each mouse was then 
briefly anesthetized by isoflurane inhalation administered either 
by nose cone or by an instrument designed for small animal an-
esthesia and a radio-frequency identification chip was implanted 
by sterile syringe beneath the dorsal skin between the shoulder 
blades, after which the wound was closed by a drop of superglue 
(Loctite	gel,	purchased	locally,	or	Nexaband	S/C,	purchased	from	
Abbott	 Laboratories).	 UM	 and	 UT	 used	 chips	 purchased	 from	
AVID	Microchip	 ID	Systems	 (Catalog	AVID3002);	TJL	used	chips	
purchased	 from	 Locus	 Technology	 (catalog	 1D-100A).	A	 portion	
of the distal tail (1 cm) was taken and frozen for later analysis of 
DNA polymorphisms, after which the mouse was permitted to 
awaken from the anesthesia. The duration of anesthesia was ap-
proximately 1–2 min.
Details of the methods used for health monitoring were provided 
in Miller et al. (2014); in brief, each of the three colonies was evalu-
ated four times each year for infectious agents, including pinworm. 
All such tests were negative throughout the entire study period.




provided a Control chow processed in the same way but with no added 
drugs, which we refer to as “Test Diets control chow.” “Test Diets control 
chow” and mouse chow containing each of the test substances were 
prepared at intervals of approximately 4 months. Mice in the Control 
group	 received	Test	Diets	Control	Chow	 (5LG6	 formulation),	without	
drugs added, from 6 months of age. Mice in cages destined to receive 
Rapa	were	given	5LG6	from	Purina	(not	Test	Diets	Control	Chow)	until	
Rapa was started at 20 months. Each batch of food was shipped at the 
same time to each of the three test sites. 17-DMAG was obtained from 
Selleckchem	Chemicals	LLC.	It	was	mixed	with	chow	at	a	concentration	
of 30 ppm and fed to mice beginning at 6 months of age. Mito Q was a 
gift	from	Mr.	Greg	McPherson,	CEO	of	MitoQ	Inc	(Auckland,	NZ).	It	was	
mixed with chow at a concentration of 100 ppm and fed to mice begin-
ning at 7 months of age. Minocycline was obtained from the UM phar-
macy.	It	is	distributed	by	Actavis	Pharma,	Inc.	It	was	mixed	with	chow	at	
a concentration of 300 mg/kg of food (300 ppm) and fed to mice begin-
ning at 6 months of age. β-GPA was purchased from Pure Chemistry 
Scientific	Inc.,	mixed	with	chow	at	a	concentration	of	3300	ppm,	and	
fed to mice beginning at 6 months of age. Microencapsulated rapamycin 
was obtained from Emtora Biosciences (formerly Rapamycin Holdings) 
and mixed at a concentration of 42 ppm. This mixture was fed to mice 
starting at 20 months of age.
4.3  |  Removal of mice from the 
longevity population
As described in detail in Miller et al. (2011), mice were removed from 
the study because of fighting, or accidental death, typically during 
chip implantation, or because of chip failure, or because they were 
used for another experimental purpose, such as testing for blood 
levels	of	a	 test	agent.	 If	used	for	experimental	purposes,	 the	mice	
were	removed	randomly	from	the	colony.	For	survival	analyses,	all	
such mice were treated as alive at the date of their removal from 
the protocol and lost to follow-up thereafter. These mice were not 
included in calculations of median longevity.
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4.4  |  Estimation of age at death (lifespan)
Mice were examined twice daily for signs of ill health. Mice were 
euthanized for humane reasons if so severely moribund that they 
were considered, by an experienced technician, unlikely to survive 
for	more	than	an	additional	48	h.	A	mouse	was	considered	severely	
moribund if it exhibited more than one of the following clinical signs: 
(a) inability to eat or to drink; (b) severe lethargy, as indicated by 
reluctance to move when gently prodded with a forceps; (c) severe 
balance or gait disturbance; (d) rapid weight loss over a period of 
1 week or more; or (e) an ulcerated or bleeding tumor. The age at 
which a moribund mouse was euthanized was taken as the best 
available estimate of its natural lifespan. Mice found dead were also 
noted at each daily inspection.
4.5  |  Statistical methods
For	each	sex,	we	performed	site-specific	and	combined	site	analy-
sis. We calculated the median survival for the control group as well 
as for each treatment group. To compute the median percentage 
increase, we subtracted the median age in the control group from 
the corresponding value in the treatment group and divided the dif-
ference by median age of the control group and multiplied by 100. 
Using a two-sided 5% significance level, we performed the log-rank 
test to determine whether survival curves for mice receiving treat-
ment	differ	 from	 the	 survival	 function	 for	 control	mice.	 Log-rank	
tests that pooled data across the three test sites used a method that 
stratifies by site. To assess the maximum lifespan, we computed 
90th percentile age of both the treated and control mice. To deter-
mine which treatments prolonged longevity in mice, we utilized the 
Wang–Allison	test	(Wang	et	al.,	2004).	This	is	the	Fisher	exact	test	
comparing the numbers of mice surviving in control and treatment 
group at the age corresponding to the 90th percentile of lifespan 
in the joint survival distribution. We further assessed the longevity 
of mice in all three sites combined using a modified version of the 
Wang–Allison test in the manner with which the 2 × 2 contingency 
table is constructed separately for each site. Basically, we report 
the sum of corresponding site-specific 2 × 2 tables cell entries as 
the combined site 2 × 2 table cell entries. This allows for informa-
tion from all sites to be used in a balanced manner.
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